SARS-CoV-2 Spike protein (S1, T19R, G142D, del 156-157, R158G, L452R, T478K, D614G, P681R, His Tag)

SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. As of May 2021, three sublineages have been found. Despite its name, B.1.617.3 was the first sublineage of this variant to be detected, in October 2020 in India. This sublineage has remained relatively uncommon compared to the two other sublineages, B.1.617.1 (also known as variant Kappa) and B.1.617.2 (also known as variant Delta), both of which were first detected in December 2020. This variant has the double mutations E484Q and L452R in the spike proteins. Emerging research suggests the variant may be more transmissible than previously evolved ones. Whether the effectiveness of currently-deployed vaccines is affected remains under investigation. Moreover, the sublineage B.1.617.2 has been redesignated as "variant of concern" (VOC-21APR-02) in May 2021, which spreads more quickly than the original version of the virus.

Price	$380.00
Cat. No.	Z03612-100
Size	100 μg 1 mg Buy in bulk
Quantity
Est. Delivery


Ask us a question

Product Introduction Background Bottom Notes

Product Introduction

Species

SARS-CoV-2

Protein Construction

Expressed with the mutations of T19R, G142D, del 156-157, R158G, L452R, T478K, D614G, P681R.

S1 protein (Gln14-Arg685) Accession # P0DTC2	Poly-His
N-term	C-term

Purity

> 90% as analyzed by SDS-PAGE

Endotoxin Level

< 0.2 EU/μg of protein by gel clotting method

Biological Activity

This protein is validated to bind with human ACE2 in functional ELISA assay.

Expression System

CHO

Theoretical Molecular Weight

75.7 kDa

Apparent Molecular Weight

~112 kDa, on SDS-PAGE under reducing conditions.

Formulation

Supplied as a solution in PBS, pH 7.4.

Concentration

Please refer to the COA for the specific lot.

Storage & Stability

Upon receiving, this product remains stable for 6 months at -20°C or below. Please avoid repeated freeze-thaw cycles.

Back

SARS-CoV-2 Spike Protein (S1, T19R, G142D, Del 156-157, R158G, L452R, T478K, D614G, P681R, His Tag)

Immobilized ACE-2 Fc Chimera, Human (Cat. No. Z03516) at 2 μg/mL can bind SARS-CoV-2 Spike protein (S1, T19R, G142D, del 156-157, R158G, L452R, T478K, D614G, P681R, His Tag) (Cat. No. Z03612) with a serial dilution.
THE^TM His Tag Antibody [HRP], mAb, Mouse (Cat.No.A00612) is used as a secondary antibody (0.2 μg/mL). »

Lane 1: 1 μg of SARS-CoV-2 Spike protein (S1, T19R, G142D, del 156-157, R158G, L452R, T478K, D614G, P681R, His Tag), reducing(R)
> 90% as analyzed by SDS-PAGE »

Background

Target Background	SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. As of May 2021, three sublineages have been found. Despite its name, B.1.617.3 was the first sublineage of this variant to be detected, in October 2020 in India. This sublineage has remained relatively uncommon compared to the two other sublineages, B.1.617.1 (also known as variant Kappa) and B.1.617.2 (also known as variant Delta), both of which were first detected in December 2020. This variant has the double mutations E484Q and L452R in the spike proteins. Emerging research suggests the variant may be more transmissible than previously evolved ones. Whether the effectiveness of currently-deployed vaccines is affected remains under investigation. Moreover, the sublineage B.1.617.2 has been redesignated as "variant of concern" (VOC-21APR-02) in May 2021, which spreads more quickly than the original version of the virus.
Synonyms	Lineage B.1.617.2; VUI-21APR-02; variant Delta
References	1. Emergence of a novel SARS-CoV-2 strain in Southern California, USA. 2. New California Variant May Be Driving Virus Surge There, Study Suggests. 3. Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351. 4. Tracking SARS-CoV-2 variants.

Back

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.

Citations

1. Kathrin Schanda, et al. Is there an immunological cross-reactivity of antibodies to the myelin oligodendrocyte glycoprotein and coronaviruses?. Brain Commun. (2024-03)